bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen
Company profile
Ticker
BPTH
Exchange
Website
CEO
Peter H. Nielsen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
OGDEN GOLF CO CORP
SEC CIK
Corporate docs
Subsidiaries
Bio-Path, Inc. ...
IRS number
870652870
BPTH stock data
Latest filings (excl ownership)
8-K
Other Events
27 Mar 24
424B5
Prospectus supplement for primary offering
27 Mar 24
8-K
Entry into a Material Definitive Agreement
26 Mar 24
RW
Registration withdrawal request
25 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Mar 24
S-1/A
IPO registration (amended)
13 Mar 24
8-K
Other Events
11 Mar 24
S-1
IPO registration
8 Mar 24
8-K
Bio-path Holdings Reports Full Year 2023 Financial Results
8 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
Transcripts
BPTH
Earnings call transcript
2023 Q4
8 Mar 24
BPTH
Earnings call transcript
2023 Q3
15 Nov 23
BPTH
Earnings call transcript
2023 Q2
15 Aug 23
BPTH
Earnings call transcript
2023 Q1
12 May 23
BPTH
Earnings call transcript
2022 Q4
31 Mar 23
BPTH
Earnings call transcript
2022 Q3
15 Nov 22
BPTH
Earnings call transcript
2022 Q2
16 Aug 22
BPTH
Earnings call transcript
2022 Q1
17 May 22
BPTH
Earnings call transcript
2021 Q4
11 Mar 22
BPTH
Earnings call transcript
2021 Q3
12 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.35 mm | 2.35 mm | 2.35 mm | 2.35 mm | 2.35 mm | 2.35 mm |
Cash burn (monthly) | 364.00 k | 941.50 k | 1.09 mm | 1.40 mm | 927.00 k | 1.23 mm |
Cash used (since last report) | 2.18 mm | 5.63 mm | 6.53 mm | 8.37 mm | 5.54 mm | 7.33 mm |
Cash remaining | 176.49 k | -3.28 mm | -4.17 mm | -6.01 mm | -3.19 mm | -4.98 mm |
Runway (months of cash) | 0.5 | -3.5 | -3.8 | -4.3 | -3.4 | -4.1 |
Institutional ownership, Q3 2023
0.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 189.00 k |
Total shares | 436.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Farther Finance Advisors | 400.00 | $173.00 k |
AllSquare Wealth Management | 36.00 | $16.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 May 23 | Morris Douglas P | Common Stock Option Common Stock | Grant | Acquire A | No | No | 1.39 | 13,000 | 18.07 k | 13,000 |
2 May 23 | Aubert Paul | Common Stock Option Common Stock | Grant | Acquire A | No | No | 1.39 | 10,000 | 13.90 k | 10,000 |
2 May 23 | Nielsen Peter Henry | Common Stock Option Common Stock | Grant | Acquire A | No | No | 1.39 | 105,000 | 145.95 k | 105,000 |
2 May 23 | Aline Sherwood | Common Stock Option Common Stock | Grant | Acquire A | No | No | 1.39 | 10,000 | 13.90 k | 10,000 |
2 May 23 | Cleaver Heath | Common Stock Option Common Stock | Grant | Acquire A | No | No | 1.39 | 10,000 | 13.90 k | 10,000 |